TY  - JOUR
T1  - Trastuzumab-induced pulmonaryfibrosis: A case report and review of literature
A1  - Tamojit Chaudhuri
A1  - Saurabh Karmakar
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2012
VL  - 1
IS  - 4
DO  - 10.4103/2278-0513.106281
SP  - 242
EP  - 244
N2  - Optimal treatment for human epidermal growth factor receptor 2 (HER2)/neu-positive, node-positive early breast cancer should include the monoclonal antibody trastuzumab. This relatively new targeted agent has shown very limited pulmonary toxicity. We report a case of Trastuzumab-induced pulmonary fibrosis in a 41-year-old female that occurred 4 months after starting adjuvant trastuzumab. To the best of our knowledge, this is the first ever report of trastuzumab-induced pulmonary fibrosis in the world of medical literature.
UR  - https://ccij-online.org/article/trastuzumab-induced-pulmonaryfibrosis:-a-case-report-and-review-of-literature-62
ER  -